1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,356 | 0,416 | 23:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 325 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 23.02. | Cantargia to Participate in TD Cowen's Annual Healthcare Conference | 362 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings... ► Artikel lesen | |
| 20.02. | Cantargia Publishes Full Year Report 2025 | 242 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports."Cantargia... ► Artikel lesen | |
| 06.02. | Invitation to the Presentation of Cantargia's Annual Results for 2025 | 281 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen | |
| 28.01. | Cantargia to Participate at Leerink Partners Global Healthcare Conference | 265 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one... ► Artikel lesen | |
| 23.01. | Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study | 204 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination... ► Artikel lesen | |
| 05.12.25 | Cantargia Provides Update on Overall Survival Data from TRIFOUR | 263 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| 19.11.25 | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal | 7 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Q3 2025 slides: First-ever profit driven by transformational Otsuka deal | 7 | Investing.com | ||
| 19.11.25 | Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse | 4 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Publishes Interim Report for January to September 2025 | 336 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11.25 | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 305 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| 05.11.25 | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 262 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10.25 | Cantargia to Participate in Upcoming Conferences | 310 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10.25 | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 346 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| 01.10.25 | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 436 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09.25 | Cantargia Closes the Acquisition of CAN10 by Otsuka | 423 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| 27.08.25 | Cantargia Granted Important US Patent for Nadunolimab | 343 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
| 21.08.25 | Cantargia Publishes Half-Year Report 2025 | 432 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
| 18.08.25 | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 500 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,70 | +1,99 % | Jetzt zuschlagen! Mit BioNTech, Vidac Pharma und Pfizer in die Krebsforschung investieren und Renditen sichern | Die globalen Gesundheitsausgaben explodieren und der Onkologie Sektor verspricht überdurchschnittliche Renditen. Während aufgrund einer immer älter werdenden Bevölkerung die Zahl der Krebsneuerkrankungen... ► Artikel lesen | |
| EVOTEC | 4,356 | +5,75 % | Evotec meldet klinischen Durchbruch mit BMS: Phase-1-Start bei "Molecular Glue" - 10 Mio. Dollar Meilenstein fließen | Evotec bekommt in der heiß umkämpften Onkologie-Pipeline einen echten Aufmerksamkeitsschub: Partner Bristol Myers Squibb (BMS) hat eine Phase-1-Studie für den CELMoD-Wirkstoff BMS-986506 gestartet.... ► Artikel lesen | |
| QIAGEN | 34,940 | +1,38 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 647,20 | +0,50 % | EQS-News: Formycon AG: Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit Regeneron und Bayer | EQS-News: Formycon AG
/ Schlagwort(e): Sonstiges
Formycon sichert Vermarktungsstart für Aflibercept-2mg-Biosimilar FYB203 in Europa und weiteren Territorien durch Settlement mit... ► Artikel lesen | |
| BRAIN BIOTECH | 2,520 | +3,70 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 0,916 | +0,99 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| CSL | 84,86 | +0,65 % | $5,000 invested in CSL shares 12 months ago is now worth… | ||
| BURCON NUTRASCIENCE | 1,260 | +4,13 % | Burcon NutraScience Corporation: Burcon Closes Second Tranche of Non-Brokered Private Placement of Convertible Debentures of up to $6.9 Million | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 1,979 | -1,32 % | MannKind Announces Settlement of Convertible Senior Notes | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,236 | +3,49 % | Ocular Therapeutix auf RBC-Konferenz: Vielversprechende Daten zu AXPAXLI | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,408 | +2,47 % | Oxford Nanopore Technologies: Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan | Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.)... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,007 | -59,38 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,444 | -0,14 % | Analyst Sentiment Unchanged After Codexis (CDXS) Earnings | ||
| CORMEDIX | 5,550 | -0,89 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | - Q4 2025 Net Revenue of $128.6 million - Pro Forma Full Year 2025 Net Revenue of $401.3 million - Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million - Conference Call Scheduled... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.